Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-3 for Injection in Acute Ischemic Stroke (Phase III)
CTR20242311Phase 3Completed
- Sponsor
- Nanjing NeuroDawn Pharmaceutical
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of loberamisal in ischemic stroke, sponsored by Nanjing NeuroDawn Pharmaceutical. Started Jun 2024; status: completed.
02
Drugs
loberamisal
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20242311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242311.